Chimeron Bio is an early-stage biotechnology company developing innovative, off-the-shelf therapies to transform cancer treatment. Our mission is to unlock the full potential of in vivo CAR-T by delivering multi-gene, multi-mechanism constructs directly inside the body. We aim to create potent, durable, and precise cell therapies that are both scalable and accessible. Our non-viral approach enables a new class of multiplex in vivo CAR-T treatments designed to tackle the complexity of solid tumors. In parallel, we are advancing complementary immuno-oncology programs to further our therapeutic impact. This disruptive approach has the potential to redefine the standard for cell and gene therapies in oncology.
| Website | http://chimeronbio.com |
| Employees | 13 (6 on RocketReach) |
| Founded | 2015 |
| Address | 601 Walnut Street Suite 825, Philadelphia, Pennsylvania 19106, US |
| Technologies |
JavaScript
,
HTML
,
PHP
+16 more
(view full list)
|
| Industry | Biotechnology Research, Biotechnology, Science and Engineering, Health Care, Therapeutics |
| Keywords | Cancer Treatment, Biotechnology, Mrna Therapeutics, Nanoparticle Drug Delivery, Tumor Microenvironment, Gene Therapy, Oncology, Precision Medicine, Targeted Therapy, Breakthrough Therapies, Drug Development, Immunotherapy, Novel Therapeutics, Biopharma, Pharmaceutical, Molecular Medicine, Biotech Research, Clinical Trials |
| Competitors | Alnylam Pharmaceuticals, CRISPR Therapeutics, bluebird bio, Editas Medicine, Precision BioSciences, Inc., Sangamo Therapeutics, Inc., G1 Therapeutics, Inc., Celyad Oncology, NantKwest, InVivo Therapeutics +43 more (view full list) |
Looking for a particular Chimeron Bio employee's phone or email?
Kevin Heyeck is the CEO and Director of Chimeron Bio.
6 people are employed at Chimeron Bio.
Chimeron Bio is based in Philadelphia, Pennsylvania.